Drugs / ALA
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT05020912 Background | Dec 2021 → Sep 2027 expected | basal cell carcinoma | Case Comprehensive Cancer Center | Active not recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ALA | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05020912 ↗ |
| Route | Topical | “At first visit, ALA applied to one BCC lesion” NCT05020912 ↗ |